Sagimet Biosciences Inc. (Nasdaq:SGMT)
Health Care/Life Sciences • Biotechnology
CIK 1400118
Company
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Address
155 Bovet Road
Suite 303
San Mateo, California 94402
155 Bovet Road
Suite 303
San Mateo, California 94402
Employees
10
10
Key Executives
Board Of Directors
Executive Chairman George W Kemble PhD |
President, Chief Executive Officer & Director David A Happel MBA |
Member-Board of Clinical Advisors Ursula Matulonis |
Member-Board of Clinical Advisors Johann Bono |
Member-Board of Clinical Advisors Duncan Jodrell |
Director Jinzi J Wu PhD |
Independent Director Elizabeth Grammer |
Independent Director Merdad V Parsey MD, PhD |
Independent Director Richard J Rodgers MBA, CPA |
Independent Director Beth C Seidenberg MD |
SEC filings
Date | Form | Event |
---|---|---|
26 Aug, 2024 | EFFECT | |
16 Aug, 2024 | 8-K | |
15 Aug, 2024 | S-3 | |
14 Aug, 2024 | 10-Q | |
14 Aug, 2024 | 8-K | |
5 Aug, 2024 | 4 | |
5 Aug, 2024 | 3 | |
5 Aug, 2024 | 3 | |
5 Aug, 2024 | 4 | |
1 Aug, 2024 | 8-K | |
25 Jul, 2024 | 4 | |
23 Jul, 2024 | 4 | |
23 Jul, 2024 | 4 | |
23 Jul, 2024 | 4 | |
23 Jul, 2024 | 144 | |
2 Jul, 2024 | 8-K | |
13 Jun, 2024 | 8-K/A | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
6 Jun, 2024 | 8-K | |
23 May, 2024 | 8-K | |
15 May, 2024 | 8-K | |
15 May, 2024 | 10-Q | |
8 May, 2024 | 3 | |
8 May, 2024 | 4 | |
6 May, 2024 | 8-K | |
18 Apr, 2024 | DEF 14A | |
18 Apr, 2024 | DEFA14A | |
18 Apr, 2024 | ARS | |
3 Apr, 2024 | 3 | |
3 Apr, 2024 | 4 | |
3 Apr, 2024 | 4 | |
3 Apr, 2024 | 3 | |
28 Mar, 2024 | 4 | |
25 Mar, 2024 | 8-K | |
25 Mar, 2024 | 10-K | |
25 Mar, 2024 | S-8 | |
11 Mar, 2024 | SC 13G/A | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
9 Feb, 2024 | SC 13G/A | |
5 Feb, 2024 | SC 13G | |
2 Feb, 2024 | 8-K | |
2 Feb, 2024 | 3 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
30 Jan, 2024 | 8-K | |
29 Jan, 2024 | 424B4 | |
25 Jan, 2024 | EFFECT | |
24 Jan, 2024 | 8-K | |
24 Jan, 2024 | S-1/A | |
23 Jan, 2024 | CORRESP | |
23 Jan, 2024 | S-1 | |
23 Jan, 2024 | CORRESP | |
22 Jan, 2024 | 8-K | |
16 Jan, 2024 | UPLOAD | |
10 Jan, 2024 | DRS | |
29 Dec, 2023 | 8-K | |
8 Dec, 2023 | 4 | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 8-K | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
20 Nov, 2023 | 4 | |
13 Nov, 2023 | 8-K | |
13 Nov, 2023 | 10-Q | |
23 Oct, 2023 | 8-K | |
27 Sep, 2023 | 8-K | |
11 Sep, 2023 | SC 13G | |
8 Sep, 2023 | 4 | |
21 Aug, 2023 | 10-Q | |
21 Aug, 2023 | 8-K | |
10 Aug, 2023 | 8-K | |
27 Jul, 2023 | 8-K | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
18 Jul, 2023 | 8-K | |
17 Jul, 2023 | S-8 | |
17 Jul, 2023 | 424B4 | IPO completed |
14 Jul, 2023 | SEC STAFF | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | S-1MEF | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | CERT | |
11 Jul, 2023 | 8-A12B | |
11 Jul, 2023 | CORRESP | |
11 Jul, 2023 | CORRESP | |
10 Jul, 2023 | CORRESP | |
10 Jul, 2023 | S-1/A | |
6 Jul, 2023 | SEC STAFF | |
6 Jul, 2023 | UPLOAD | |
3 Jul, 2023 | S-1/A | |
23 Jun, 2023 | S-1 | |
15 May, 2023 | SEC STAFF | |
11 May, 2023 | DRS/A | |
10 May, 2023 | DRSLTR | |
25 Apr, 2023 | DRS/A | |
25 Apr, 2023 | DRSLTR | |
20 Apr, 2023 | UPLOAD | |
24 Mar, 2023 | DRS | |
21 Mar, 2022 | RW | |
10 May, 2021 | S-1/A | |
16 Apr, 2021 | S-1 | |
11 Mar, 2021 | DRS | |
5 Jan, 2021 | D |
Last update:2024-03-06 12:23:30.502429
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.